
Ocular Therapeutix rated Buy with $7.90 target after strong Phase 3 results and expected 2027 launch.
Ocular Therapeutix received a Buy (speculative) rating with a 12-month price target of $7.90 following strong Phase 3 SOL-1 trial results. The positive data supports a clear regulatory path, with a New Drug Application (NDA) filing expected in Q4 and...





